Compare CRBU & SMTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRBU | SMTI |
|---|---|---|
| Founded | 2011 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 203.9M | 182.6M |
| IPO Year | 2021 | 2008 |
| Metric | CRBU | SMTI |
|---|---|---|
| Price | $1.82 | $18.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $10.00 | ★ $41.00 |
| AVG Volume (30 Days) | ★ 1.2M | 51.7K |
| Earning Date | 06-08-2026 | 04-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.64 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $15,586,976.00 |
| Revenue This Year | N/A | $20.66 |
| Revenue Next Year | $5.37 | $13.97 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 32.47 |
| 52 Week Low | $0.66 | $18.29 |
| 52 Week High | $3.53 | $35.70 |
| Indicator | CRBU | SMTI |
|---|---|---|
| Relative Strength Index (RSI) | 51.92 | 37.65 |
| Support Level | $1.71 | $18.60 |
| Resistance Level | $2.11 | $21.18 |
| Average True Range (ATR) | 0.15 | 1.10 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 38.03 | 19.38 |
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.
Sanara MedTech Inc is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the chronic and surgical wound and skincare markets. Its portfolio of products and services allows it to deliver comprehensive wound and skincare solutions for patients in all care settings, including acute and post-acute. Its surgical wound care products are CellerateRX Surgical Activated Collagen. Its chronic wound care products are BIAKOS Skin and Wound Cleanser, and BIAKOS Skin and Wound Gel.